Search

Displaying results 2751 - 2760 of 10000 in total
  1. Drug

    Equine Botulinum Neurotoxin B Immune FAB2

    go.drugbank.com/drugs/DB13903
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes B in adults and pediatric patients. … Equine Botulinum Neurotoxin B Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype B.

  2. Drug

    Ticagrelor

    go.drugbank.com/drugs/DB08816
    ApprovedInvestigational

    [A2903] Unlike [clopidogrel], ticagrelor is not a prodrug.[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. … Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism.

  3. Drug

    Aluminum zirconium tetrachlorohydrex gly

    go.drugbank.com/drugs/DB11149
    ApprovedWithdrawn

    Aluminum zirconium tetrachlorohydrex gly is a common active ingredient in personal care products as an antiperspirant agent. … Its main mechanism of action is through blocking the pores via formation of polymer complex and preventing sweat from leaving the body.

    Mixtures: Ban Ultra Antiperspirant Roll-ONProducts: Degree Roll-ON Antiperspirant, Ban Clear Ap Roll-ON
  4. Drug

    Volanesorsen

    go.drugbank.com/drugs/DB15067
    Approved

    [L16621] This drug is not commonly prescribed as it is used as an adjunct to diet in patients at high risk for pancreatitis, who have had inadequate response to triglyceride lowering therapy. … Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA to prevent its translation.

  5. Drug

    Equine Botulinum Neurotoxin G Immune FAB2

    go.drugbank.com/drugs/DB13899
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and pediatric patients. … Equine Botulinum Neurotoxin G Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype G.

  6. Drug

    Equine Botulinum Neurotoxin D Immune FAB2

    go.drugbank.com/drugs/DB13902
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients. … Equine Botulinum Neurotoxin D Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype D.

  7. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    [A274878] The WAS protein is expressed on non-erythroid hematopoietic cells and regulates the function of actin filaments in the cytoskeleton.[A274878] … [L54698] First approved by the FDA on December 9, 2025, etuvetidigene autotemcel is used to treat Wiskott–Aldrich syndrome (WAS) in selected pediatric and adult patients.

  8. Drug

    Bisoprolol

    go.drugbank.com/drugs/DB00612
    ApprovedInvestigational

    It may be used alone or in combination with other drugs to manage hypertension[L7219] and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity. … [A180472] Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such

  9. Drug

    Fecal microbiota

    go.drugbank.com/drugs/DB17743
    ApprovedInvestigational

    Fecal microbiota, given either as a rectal transplant or in an oral formulation of live spores, is an FDA-approved option to prevent the recurrence of _Clostridioides difficile_ infection (CDI) in patients … [A259172] REBYOTA, a live fecal microbiota suspension for rectal use, was approved by the FDA in November 2022.

  10. Drug

    Streptococcus pneumoniae type 5 capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10295
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … Streptococcus pneumoniae type 5 capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae*

    Mixtures: PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, 10 ADET